Court Report

    By Sherri Oslick --

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.

Celgene Corporation et al. v. Barr Laboratories, Inc. et al.
2:07-cv-05256; filed October 31, 2007 in the District Court of New Jersey

Infringement of U.S. Patent Nos. 5,837,284 ("Delivery of Multiple Doses of Medications," issued November 17, 1998) and 6,635,284 (same title, issued October 21, 2003) (both assigned to Celgene and licensed exclusively to Novartis in certain fields of use) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Novartis' Ritalin® LA (methylphenidate hydrochloride extended release capsules, used to treat attention deficit hyperactivity disorder/attention deficit disorder).  View the complaint here.

Elan Corporation PLC et al. v. Actavis South Atlantic LLC
1:07-cv-00679; filed October 29, 2007 in the District Court of Delaware

Infringement of U.S. Patent Nos. 6,228,398 ("Multiparticulate Modified Release Composition," issued May 8, 2001) and 6,730,325 (same title, issued May 4, 2004), licensed to Novartis, following a paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Novartis' Focalin® XR (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder).  View the complaint here.

Medeva Pharma Suisse A.G. et al. v. Roxane Laboratories, Inc.
3:07-cv-05165; filed October 26, 2007 in the District Court of New Jersey

Infringement of U.S. Patent No. 5,541,170 ("Orally Administrable Pharmaceutical Compositions," issued July 30, 1996) following a paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of plaintiffs' Asacol® (mesalamine, used to treatment ulcerative colitis).  View the complaint here.

Aventis Pharmaceuticals Inc. et al. v. Dr. Reddy's Laboratories, Ltd. et al.
2:07-cv-05180; filed October 26, 2007 in the District Court of New Jersey

Infringement of U.S. Patent Nos. 6,399,632 ("Method of Providing an Antihistaminic Effect in a Hepatically Impaired Patient," issued June 4, 2002), 6,187,791 (same title, issued February 13, 2001), and 6,037,353 (same title, issued March 14, 2000), 6,113,942 ("Pharmaceutical Composition for Piperidinoalkanol Compounds," issued September 5, 2000), 5,855,912 (same title, issued January 5, 1999), and 5,738,872 (same title, issued April 14, 1998) following a paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Aventis' Allegra-D® 24 Hour (fexofenadine hydrochloride/ pseudoephedrine, used to treat allergies).  View the complaint here.

Sepracor Inc. et al. v. Perrigo Research And Development Company et al.
3:07-cv-05136; filed October 25, 2007 in the District Court of New Jersey

Infringement of U.S. Patent Nos. 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007) and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007), licensed to Schering-Plough, following a paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex® (desloratidine, used to treat allergies).  View the complaint here.